Filing Flows › Alkermes (ALKS) › Q4 2025
Alkermes (ALKS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 25, 2026
Alkermes (ALKS) reported revenue of $385M for the fourth quarter 2025 (Q4 2025), -11% from a year earlier and -2% from the quarter before. Operating margin was 15.1%, net earnings $49.3M (12.8% of revenue).
Alkermes, Q4 2025: revenue $385M (-11% year over year), operating margin 15.1%, net earnings $49.3M, operating cash flow $170M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $385M | -2% | -11% |
| Operating profit | $58.1M | -35% | -64% |
| Net earnings | $49.3M | -40% | -66% |
| Operating cash flow | $170M | +67% | -11% |
What changed
Revenue was $384.5M in Q4 2025, down 11% year over year and down 2% from the previous quarter. Vivitrol was the largest line at 32% of revenue.
Operating profit was $58.1M, a 15.1% margin (down 22.7 points year over year). Total costs grew 22% against a revenue fall of 11%. The fastest-growing cost line was Research & development (+60%). Net earnings were $49.3M, down 66% year over year. The effective tax rate was 18.3%.
Operating cash flow was $170.1M (down 11% year over year), 345% of net earnings. Non-cash charges added back $3.8M of depreciation and amortization and $26.3M of share-based compensation. Working capital and other items added $90.6M. Capital expenditures of −$20K left free cash flow of $170.1M.
Questions
What was Alkermes' revenue in the fourth quarter 2025?
Alkermes (ALKS) reported revenue of $385M for the fourth quarter 2025 (Q4 2025), -11% from a year earlier and -2% from the quarter before.
Was Alkermes profitable in the fourth quarter 2025?
Operating profit was $58.1M (15.1% of revenue) and net earnings $49.3M.
Source: Alkermes 10-K on SEC EDGAR.